Concept Life Sciences Makes Scientific and Commercial Leadership Appointments
Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has appointed Dr Michael Donaldson as Principal Scientist in its Dermal department, and Dr Tim Calvert as Vice President of Business Development, Integrated Discovery Services, Europe.
Tim has extensive experience in the delivery of integrated drug discovery and development solutions, supporting organisations ranging from virtual companies to global pharma. Tim joins Concept from Aptuit where he held various roles, most recently Senior Director of Integrated Drug Development, during which time he was responsible for executing complex and accelerated drug development programmes. Prior to joining Aptuit, he was at Lonza, where he led and secured Israel’s first gene therapy development programme, Catalent Pharma Solutions, and Invitrogen.
Michael has over 17 years’ experience in the pharmaceutical development and manufacturing industry. Most recently he was Director of Biology in Dermatology Therapy Area at GlaxoSmithKline. Previous experience includes formulation and manufacturing at Stiefel, a GSK company, development of skin permeation products at MedPharm, and developing liquid chromatography methods for antibiotic production analysis within the QC/QA group at Roche Pharmaceuticals. In his new role at Concept, Michael will be responsible for Dermal Services.
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “We are delighted to welcome Michael and Tim to Concept. Their notable scientific and commercial backgrounds will be invaluable in supporting the continued expansion of the group.”
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE